Camp4 Therapeutics (CAMP) Non-Current Deffered Revenue (2025 - 2026)
Camp4 Therapeutics' (CAMP) quarterly Non-Current Deffered Revenue came in at $5.2 million in Q1 2026, down 35.72% quarter-over-quarter from $8.1 million in Q4 2025.
Camp4 Therapeutics (CAMP) Non-Current Deffered Revenue (2025 - 2026) Analysis & Trends
Camp4 Therapeutics has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $5.2 million for Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $5.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (changed N/A YoY), and the FY2025 annual result was $8.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $5.2 million for Q1 2026 at Camp4 Therapeutics, down from $8.1 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $8.1 million in Q4 2025 to a low of $5.2 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Camp4 Therapeutics | 245.02 Mn | 245.02 Mn | - | 5.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.22 Mn |
| Dec 31, 2025 | 8.11 Mn |